Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Verastem enters its November 6 earnings window with a genuinely split picture: a stock that has quietly recovered to $8.27, analysts uniformly bullish but priced well above where the shares trade, and a short position at 24.8% of float that refuses to budge.
Short interest is the defining feature of the positioning story right now. At nearly a quarter of the free float, the bear position has barely moved across the past month, up just 1.9% on the week and 1.2% over thirty days. That stickiness is notable because the borrow market offers no obvious headwind for shorts: availability runs at 292% of short interest, meaning there are roughly three shares available to borrow for every two already lent, well above the level that would signal squeeze pressure. Cost to borrow ticked up 14% this week to 0.46%, but that is still exceptionally cheap for a name this heavily shorted. The ORTEX short score has drifted higher to 66.97, near the top of its recent range, reflecting the combination of elevated short interest and improving price momentum. Shorts are not panicking. The borrow market gives them no reason to.
Options positioning has tilted noticeably call-heavy, which on the surface looks bullish but cuts both ways. The put/call ratio of 0.22 sits more than 2.4 standard deviations above its 20-day mean of 0.197. In a name with this much short interest, a PCR this low typically reflects call-driven speculation rather than outright bearish hedging. Traders are reaching for upside exposure, not protection.
The Street is unified in direction but split on conviction. BTIG reiterated its Buy with an $18 target on October 8, and HC Wainwright matched that call on October 5. Wolfe Research opened coverage at Outperform in September, a fresh voice adding to the bullish chorus. The mean target across the covering group is $15.00, against a current price of $8.27, implying roughly 81% upside on the consensus view. However, Guggenheim sits at $12 and Mizuho at $13 after both trimmed targets in August, a reminder that the high-end targets from BTIG and HC Wainwright dominate the mean. The analyst recommendation divergence factor score ranks in the 92nd percentile, meaning the skew toward positive ratings is unusually high relative to the broader universe. The bull case rests on avutometinib plus defactinib's durability data in low-grade serous ovarian cancer, including a 22.1-month weighted median PFS in KRAS-mutant disease and a growing pipeline of registrational trials under the TARGET-D program. Bears focus on the company's dependence on a single franchise, the distance between current fundamentals and the NPV-based valuation anchored to 2037 earnings estimates, and the dilution risk that comes with any cash need before the program reaches profitability.
Institutional ownership adds an interesting layer. BlackRock reported holding 10.2% of shares as of September 30, a position that grew by nearly 3 million shares in the most recent period. State Street similarly added 1.6 million shares in the same quarter. Both are passive-linked flows rather than active conviction bets, but the net direction is accumulation, not distribution. Specialist biotech holders including RTW Investments, Deep Track Capital, and Armistice Capital each sit above 7% of shares, providing a concentrated ownership base that tends to limit liquidity for shorts seeking to cover quickly if the clinical story accelerates. The activist register carries no 13D filings, all known large holders have filed on passive Schedule 13G forms, though several, including Nantahala and Logos, have trimmed from earlier peaks above 6%.
Recent insider activity is routine rather than signal-generating. The CEO and CFO both sold small quantities on October 1 and through late September, all under pre-arranged 10b5-1 plans and in individually modest size. The net 90-day insider position is negative at around $381,000 in sales, but none of these trades represent discretionary conviction selling.
Earnings history is the sharpest number in the snapshot: the two most recent prints both produced next-day moves of approximately 14.8% to 14.9%, with five-day follow-through in the 11% to 14% range. Both moves were positive. With the next report scheduled for November 6, twenty-nine days away, how the stock behaves into that date, and whether the current short position begins to move ahead of it, is the clearest thing to watch from here.
See the live data behind this article on ORTEX.
Open VSTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
